FDA yes for Salix's previously delayed Ruconest
This article was originally published in Scrip
Salix Pharmaceuticals has received a green light from the US FDA to market Ruconest (recombinant C1 esterase inhibitor) for the treatment of acute angioedema attacks in adult and adolescent patients with hereditary angioedema (HAE).
You may also be interested in...
Angeli Möller, recently spotlighted by In Vivo as a 2020 Rising Leader, has quickly moved up the ranks at Bayer and is now spearheading one of its key initiatives to bring artificial intelligence and machine learning technologies into the pharma business.
Coaching and mentoring are important tools for the leaders of today to be able to foster the next generation of talent in the biopharma sector. While the routes into industry have not changed dramatically – most leaders hold a master’s degree and/or PhD – the expectations of rising leaders have altered and the industry itself has become more collaborative.
In this first edition of In Vivo's ‘Rising Leaders’ list, the focus is on entrepreneurs and innovators who represent the next wave of creativity in health care.